Clinical worsening also occurred less frequently with treprostinil ...

Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive, fatal disease of unknown cause. Although there is no known cure, there have been indications that gastroesophageal reflux disease (GERD) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Studies set to assess pamrevlumab in IPF have been ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

Baseimmune, a biotechnology company leveraging computational protein design to create next-generation immunotherapies, today ...

The 2011 ATS/ERS/JRS/ALAT guidelines list a number of recommendations for the diagnosis and clinical management of patients with IPF The level of understanding and adherence to the guidelines among ...

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic coughFirst pivotal ...

Pulmonary Fibrosis Xray Investigators developed a timeline reflecting the diagnosis and treatment of idiopathic pulmonary fibrosis in the US. The average time to diagnosis of IPF was 2.7 years after a ...

Randomized, placebo-controlled study to evaluate safety, tolerability, and potential for positive impact on lung functionAUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") ...

Please provide your email address to receive an email when new articles are posted on . An online survey was created to capture the burden of IPF. Patients frequently reported shortness of breath. IPF ...

Current idiopathic pulmonary fibrosis (IPF) trials often exclude diverse patient perspectives, leading to unrepresentative conclusions and limited patient engagement. Issues identified include ...